Metasol (Methylprednisolone Hydrogen Succinate)

Methylprednisolone hydrogen succinate binds to intracellular glucocorticoid receptors, forming a complex that enters the nucleus and modulates gene transcription. This process up‑regulates anti‑inflammatory proteins while suppressing pro‑inflammatory cytokines, leading to reduced leukocyte migration, decreased capillary permeability, and overall immunosuppression.

The dose of Metasol is individualized by the prescribing clinician based on the specific indication, severity of the condition, patient weight, renal and hepatic function, and response to therapy. No fixed regimen is provided here; the prescriber will calculate the appropriate amount and infusion rate for each patient.

Safety data for methylprednisolone hydrogen succinate in pregnancy and lactation are limited. The drug should be used only if the potential benefit justifies the potential risk to the fetus or infant. Breastfeeding mothers should discuss possible effects with their healthcare provider, as glucocorticoids can be excreted in breast milk.

To place an order, submit an enquiry on the Metasol product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Metasol delivers methylprednisolone as an intravenous formulation, offering rapid onset compared with oral or intramuscular glucocorticoids. Its potency is roughly equivalent to other high‑dose IV steroids such as dexamethasone, but the specific pharmacokinetic profile and dosing flexibility may differ. Choice of agent depends on clinical setting, required speed of action, and physician preference.

Metasol should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from direct sunlight, moisture, and extreme temperature fluctuations. Do not freeze the solution, and discard any vial that appears discolored or contains particulate matter.

Metasol is given by intravenous infusion. The vial is typically reconstituted with a compatible diluent, then administered slowly over a period determined by the prescriber—often 30–60 minutes for acute indications. Administration should be performed by qualified healthcare personnel in a setting equipped to monitor vital signs and manage potential reactions.

Serious risks include adrenal suppression or crisis if therapy is stopped abruptly, severe infections due to immunosuppression, gastrointestinal bleeding, anaphylaxis, and profound hyperglycemia that may lead to ketoacidosis. Patients should be monitored closely for signs of infection, blood‑glucose changes, and any unexpected psychiatric symptoms.

Metasol is contraindicated in patients with known hypersensitivity to methylprednisolone or any component of the formulation, and in those with systemic fungal infections that require systemic antifungal therapy. Caution is also advised for individuals with uncontrolled viral infections, severe osteoporosis, or uncontrolled diabetes, where the risk‑benefit ratio must be carefully evaluated.